GI Effects Maldigestion Score

If you have been losing weight without trying, dealing with greasy stools, or running into nutrient deficiencies your doctor cannot explain, the question is often the same: is food actually getting broken down before it leaves your gut? The Maldigestion Score is one attempt to answer that with a single number drawn from a stool sample.

It is a composite, not a stand-alone biomarker. Several stool markers are folded together to estimate how much of what you eat is being properly digested versus passing through intact. Treat it as one input worth investigating when symptoms or risk factors are present, not as a final diagnosis on its own.

What the Score Actually Measures

The Maldigestion Score is part of the GI Effects Comprehensive stool panel from Genova Diagnostics. It draws on stool measurements that each reflect a different piece of the digestion process. The most clinically validated component is pancreatic elastase-1, an enzyme released by your pancreas that survives the trip through your gut and shows up in your stool. Low elastase means your pancreas is not putting out enough digestive enzymes.

The GI Effects panel also reports stool fat measurements and short-chain fatty acid patterns that reflect how protein and fat are being processed. How exactly these are combined into the Maldigestion Score is proprietary to the lab and has not been described in peer-reviewed studies, so the composite itself should be read as a directional signal rather than a precise number.

Because this is a proprietary composite, the score itself does not have published reference ranges in the peer-reviewed literature. The clinical interpretation comes from the components, particularly elastase, which is well-validated on its own.

Exocrine Pancreatic Insufficiency

The condition this score is most useful for catching is exocrine pancreatic insufficiency, or EPI. EPI happens when your pancreas no longer makes enough enzymes to break down fat, protein, and carbohydrates. It causes bloating, oily stools, weight loss, fat-soluble vitamin deficiencies, and protein-calorie malnutrition that build up over years.

Fecal elastase-1, the main driver of the Maldigestion Score, is considered a sensitive screening tool for EPI in higher-risk groups: a 2025 meta-analysis found a pooled sensitivity of about 0.94 and specificity of about 0.69 at the standard 200 micrograms per gram cutoff. The moderate specificity is why it works best when there is already a clinical reason to suspect EPI. In low-prevalence settings, the false-positive rate goes up, and guideline groups caution against using it as a first-line test for nonspecific chronic diarrhea, where infection, inflammation, or medications are more likely culprits. The test is also insensitive to mild EPI and should be run on a formed, not watery, sample to avoid dilutional false positives.

EPI is not rare among people with established risk factors. The American Gastroenterological Association lists chronic pancreatitis, relapsing acute pancreatitis, pancreatic cancer, cystic fibrosis, and previous pancreatic surgery as high-risk conditions, and celiac disease, Crohn's disease, previous intestinal surgery, longstanding diabetes, and hypersecretory states as moderate-risk. EPI has also been described in people living with HIV on antiretroviral therapy and after esophagectomy. Treating confirmed EPI with pancreatic enzyme replacement therapy improves fat and protein digestion, weight, nutrition, and quality of life, and failure to dose adequately is associated with continued malnutrition and worse outcomes.

Aging and the Pancreas

Several studies suggest your pancreas tends to put out less enzyme as you age. A systematic review reported that about 5 percent of adults over 70 and 10 percent over 80 have fecal elastase values low enough to suggest pancreatic insufficiency. Not every study has found the same pattern, and at least some work has not shown a clear age-related decline in healthy older adults, so this is a tendency rather than a universal rule. Where the decline does happen, it can contribute to silent shortfalls in nutrition even in people who feel well.

If you are older, have GI symptoms, or are tracking unexplained nutrient deficiencies, an elastase-driven score like this can be one input. Pair it with a nutrient panel rather than treating it in isolation, and do not use it as a routine screen in the absence of symptoms or risk factors.

Diabetes and Digestive Function

Type 2 diabetes is linked to a broad range of GI problems. In a cohort of about 374,000 adults, people with type 2 diabetes had higher risk of gastritis, peptic ulcer, fatty liver, pancreatitis, and several hepatobiliary cancers. The authors argued for earlier detection of digestive problems in this group.

Fecal elastase values are often lower in both type 1 and type 2 diabetes than in non-diabetic adults, with reported prevalences of low elastase ranging from roughly 26 to 57 percent in type 1 and 20 to 36 percent in type 2. The AGA notes that longstanding type 1 diabetes diminishes pancreatic enzyme secretion and elastase levels but does not by itself cause clinical EPI, and many studies have not excluded underlying pancreatic disease. If you are managing diabetes and have digestive symptoms that do not match your blood sugar control, looking at maldigestion markers can be a reasonable step, but a low elastase in this setting needs careful interpretation rather than automatic treatment.

When Results Can Be Misleading

Because the Maldigestion Score depends partly on stool fat content, what you eat in the days before collecting your sample can shift the result. Eat unusually low fat and you may underestimate true maldigestion. Eat unusually high fat and you may push the score upward without a real pancreatic problem.

• Diet right before the test: dramatic short-term changes in fat intake can shift stool fat values, which feed into the composite score.
• Watery or diarrheal stool: fecal elastase is meant to be measured on formed stool, and watery samples can produce falsely low values through dilution.
• Acute illness: changes in transit time and stool consistency can make a single reading unrepresentative.
• Recent antibiotics or laxatives: both alter stool composition enough to make a single sample unrepresentative of your normal physiology.
• Pancreatic enzyme supplements: if you are already taking enzymes, the score reflects life on therapy, not your underlying pancreatic capacity.

The composite nature of the score is itself a confounder. Two people can land on the same number for very different reasons, one because of low pancreatic output, another because of upstream issues with stomach acid or transit. The components matter more than the headline number.

Why One Reading Is Not Enough

A single stool sample captures one window of your digestion under whatever conditions existed in the 24 to 72 hours before collection. That is a thin slice. The same person can produce different stool marker values across consecutive days depending on diet, hydration, and stool form.

A more useful approach is to treat your first result as a baseline. If the score is elevated or low, retest in 3 to 6 months under similar conditions, especially after any change in diet, enzyme support, or treatment for an underlying condition. For people with chronic pancreatitis, regular monitoring of pancreatic function is reasonable and is supported by recent reviews. No major guideline recommends routine yearly maldigestion screening for all adults with diabetes or for everyone over 60. Retesting in those groups makes more sense when symptoms or new findings prompt it, rather than on a fixed calendar.

Trend matters more than any single number. A steadily rising score over consecutive tests, even within so-called normal ranges, tells you something about trajectory that a single value cannot.

What to Do With an Out-of-Pattern Result

If your Maldigestion Score is elevated, the next step is not to act on the composite. It is to look at the components. A low pancreatic elastase points toward pancreatic insufficiency and warrants confirmatory testing, often with a repeat elastase or a direct pancreatic function test. Elevated stool fat with normal elastase suggests the problem is somewhere else: bile acid handling, small intestinal bacterial overgrowth, or transit issues.

Order companion tests at the same time as you retest. A full GI Effects panel adds information on inflammation, microbiome balance, and absorption that helps locate where digestion is going wrong. Standard blood work for fat-soluble vitamins (A, D, E, K), B12, iron, and albumin tells you whether maldigestion is already showing up as nutrient loss. An HbA1c reading helps assess whether diabetes is part of the picture.

If pancreatic insufficiency looks likely, the appropriate next step is a conversation with a gastroenterologist about pancreatic enzyme replacement therapy and imaging of the pancreas. Do not start enzymes on your own based on a screening composite. The treatment works when matched to a real diagnosis.